

Publikationen 2000

Originalpublikationen in wissenschaftlichen Zeitschriften

1. Bürgisser P, Vernazza P.L, Flepp M, Böni J, Tomasik Z, Hummel U, Pantaleo G, Schüpbach J. and the Swiss HIV Cohort Study. Performance of five different assays for the quantification of viral load in subjects infected with various subtypes of HIV-1. *J. Acquir. Immune Defic. Syndr* 2000;23:138-144.
2. Brunner S, Ruef C, Fleisch F, Altwegg M. Automated ribotyping and pulsedfield gel electrophoresis of invasive group A streptococci reveal an epidemic in patients with intravenous drug use. *Infection* 2000; 28:314-317.
3. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, LoBue PA, Peter C, Pfyffer GE, Sierra MF, Weber R, Woods G, Mathews G, Jonas V, Smith K, Della-Latta P. The Role of Clinical Suspicion in Evaluating a New Diagnostic Test for active Tuberculosis: Results of a Multicenter Prospective Trial. *JAMA [J Am Med Assoc]* 2000;283:639-645.
4. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) Viruses. *J Virol.* 2000;74:4933-4937.
5. Couzinet S, Cejas E, Schittny J, Deplazes P, Weber R, Zimmerli S. Phagocytic uptake of Encephalitozoon cuniculi by non-professional phagocytes. *Infect Immun* 2000;86:6939-6945.
6. Durrer P, Zbinden R, Fleisch F, Altwegg M, Ledergerber B, Karch H, Weber R. Intestinal Infection Due to Enteroaggregative Escherichia coli among Human Immunodeficiency Virus-Infected Persons. *J Inf Dis* 2000;182:1540-1544.
7. Ersch J, Speich R, Weber R, Altwegg M, Hauser M. Stellenwert der bronchoalveolären Lavage in der Abklärung HIV-assoziiierter Lungenerkrankungen. *Dtsch Med Wschr* 2000;125:789-793.
8. Flechsig E, Shmerling D, Hegyi I, Raeber A.J, Fischer M, Cozzio A, von Mering C, Aguzzi A, Weissmann,C. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. *Neuron* 2000;27:399-408.
9. Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: Also occurring with Levofloxacin. *Infection* 2000;28:256-257
10. Fischer M, Günthard H, Opravil M, Joos B, Huber W, Bisset LR, Ott P, Böni J, Weber R, Cone RW. Residual HIV-RNA levels persist for up to 2.5 years in PBMC of patients on potent antiretroviral therapy *AIDS Res Hum Retroviruses* 2000;16:1135-1140.
11. Friedl AC, Attenhofer Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, Linka A, Weber R. Acceleration of proven coronary artery disease among HIVinfected patients on potent antiretroviral therapy. [Research Letter] *AIDS* 14:2790-2792.

12. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M, for the Swiss HIV Cohort Study. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. [Research letter] *Lancet* 2000; 355: 2217-2218.
13. Furrer H, Telenti A, Rossi M, Ledergerber B for the Swiss HIV Cohort Study. Discontinuing or withholding primary prophylaxis against *M. avium* in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. *AIDS* 14:1409-1412, 2000.
14. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A for the Swiss HIV Cohort Study. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000;356:1800-1805.
15. Grivel JC, Penn ML, Eckstein DA, Schramm B, Speck RF, Abbey NW, Herndier B, Margolis L, Goldsmith MA. Human Immunodeficiency Virus Type 1 Coreceptor Preferences Determine Target T-Cell Depletion and Cellular Tropism in Human Lymphoid Tissue. *J Virol* 2000;74:5347-5351.
16. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of Influenza Vaccination on Viral Replication and Immune Response in HIV Infected Persons Receiving Potent Antiretroviral Therapy. *J Inf Dis* 2000;181(2):522-531
17. Joly V, Moroni M, Concia E, Lazzarin A, Hirschel B, Jost J, Chiodo F, Bentwich Z, Love WC, Hawkins DA, Wilkins EG, Gatell AJ, Vetter N, Greenwald C, Freimuth WW, de Cian W. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. *Antimicrob Agents Chemother* 2000;44(11):3155-3157.
18. Joos B, Fischer M, Opravil M, Ott P, Weber R, Cone RW. Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1 infected cells. [letter] *AIDS* 2000;14:752-754.
19. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S on behalf of the CNA3002 European Study Team. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a double-blind, trial. *AIDS* 2000;14(7):781-789.
20. Knuchel MC, Speck RF, Schlaepfer E, Kuster H, Ott P, Günthard HF, Opravil M, Cone RW, Weber R. Impact of TNFa , LTa , Fcg RII, and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. *AIDS* 2000;14:2661-2669.
21. Knuchel MC, Graf B, Schläpfer E, Kuster H, Fischer M, Weber R, Cone RW. PCR-derived ss DNA probes for fluorescent in situ hybridization to HIV-1 RNA. *J Histochem Cytochem* 2000;48:285-293.

22. Knuchel MC, Kuster H, Schlaepfer E, Kallivroussis A, Weber R, Cone RW. Incomplete HIV-1 activation in latently infected U1 cells demonstrated by double in situ hybridization. *Virology* 2000;271:79-89.
23. Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Günthard H, Lüthy R, Weber R, Cone RW. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. *Am J Pathol* 2000;156: 973-1986.
24. Ledergerber B, Flepp M, Böni J, Tomasik Z, Cone RW, Lüthy R, Schüpbach J. HIV-1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with CD4+ decline, progression to AIDS and survival: Comparison with viral RNA. *J Inf Dis* 181:1280-1288,2000.
25. Martinez-Picado J., DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E, Günthard HF, Sutton L, Savara A., Petropoulos C, Hellmann N, Walker BD, Richman DD, Siliciano R, D'Aquila RT. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. *PNAS* 2000;97(20):10948-10953.
26. Morgan U, Weber R, Xiao L, Sulaiman I, Thompson RCA, Ndiritu W, Lal A, Deplazes P. Molecular characterisation of *Cryptosporidium* isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya and the USA. *J Clin Microbiol* 2000;38:1180-1183.
27. Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. *J Acquir Immune Defic Syndr* 2000;23:128-137.
28. Opravil M, Cone RW, Fischer M, Vernazza PL, Bassetti S, Lorenzi P, Bisset LR, Ott P, Huber W, Knuchel MC, Roos M, Lüthy R, Weber R, and the Swiss HIV Cohort Study. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. *J Acquir Immune Defic Syndr* 2000;23:17-25.
29. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Zwahlen C, Trkola A, Clapham PR, Wells TN. The BBXB motif of RANTES is the principal site for heparin binding, and controls receptor selectivity. *J Biol Chem* 2000; Dec 14 (publication ahead of print)
30. Precious HM, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ. Multiple Sites in HIV-1 Reverse Transcriptase Associated with Virological Response to Combination Therapy. *AIDS* 2000;14:31-36.
31. Rutschmann OT, Vernazza PL, Bucher HC, Opravil M, Ledergerber B, Telenti A, Malinverni R, Bernasconi E, Fagard C, Leduc D, Perrin L, Hirschel B, and the Swiss HIV Cohort Study. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. *AIDS* 2000,14:2145-2151.

32. Schramm B, Penn ML, Speck RF, Chan SY, De Clercq E, Schols D, Connor RI, Goldsmith MA. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. *J Virol* 2000;74:184-192.
33. Smith D, Berrey MM, Robertson M, Mehrotra D, Markowitz M, Perrin L, Clumeck N, Lazzarin A, Burckhardt B, Weber R, Corey L, Cooper DA. Virological and immunological effects of combination antiretroviral therapy, with zidovudine, lamivudine and indinavir, during primary HIV-1 infection. *J Infect Dis* 2000;182:950-954.
34. Somaini B, Wang J, Perozo M, Kuhn F, Meili D, Grob P, Flepp M. The Zurich Prometheus Study Group. (2000) A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programs in Zurich, Switzerland. *AIDS Care* 12:449-460.
35. Speck RF, Esser U, Deen KC, Atchison RE, Sweet R, Goldsmith MA. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV-1. *AIDS Res Hum Retrovir* 2000;16:1845-1854.
36. The European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. *AIDS* 2000;14:2913-2920
37. Vernazza P.L, Troiani L, Flepp M.J, Cone R.W, Schock J, Roth F, Boggian K, Cohen M.S, Fiscus S.A, Eron J.J. and the Swiss HIV Cohort Study (2000) Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. *AIDS* 2000;14:117-121.
38. Weber R, Pusterla N, Loy M, Leutenegger CM, Schär G, Baumann D, Wolfensberger C, Lutz H. Serologische und klinische Daten weisen auf das endemische Vorkommen der humanen granulozytären Ehrlichiose in der Nordostschweiz hin. *Schweiz Med Wschr* 2000;130:1462-1470.
39. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, Furrer H, Hirschel B, Perrin L, and the Swiss HIV Cohort Study. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. *AIDS* 2000;14:243-249 .

Originalpublikationen im Rahmen der Schweiz. HIV-Kohortenstudie oder anderer Studiengruppen

1. Saillour-Glénisson F, Chêne G, Salmi LR, Hafner R, Salamon R, et le groupe méta-analyse dapsone. Effet de la dapsone sur la survie des patients infectés par le VIH: une méta-analyse des essais terminés. [Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials]. *Rev Epidemiol Sante Publique* 2000;48:17-30.
2. Stoeckli TC, Steffen-Klopstein I, Erb P, Brown TM, Kalish ML, and the Swiss HIV Cohort Study. Molecular epidemiology of HIV-1 in Switzerland. *J Acquir Immune Defic Syndr* 2000;23:58-67.
3. Sudre P, Rickenbach M, Taffé P, Janin P, Volkart AC, Francioli P, and the Swiss HIV Cohort Study. Clinical epidemiology and research on HIV infection in

Switzerland: the Swiss HIV Cohort Study 1988-2000. *Schweiz Med Wochenschr* 2000;130:1493-500.

Übersichtsartikel

1. Bürki B, Flepp M, Saller R, Tuchschnid A, Hüsler G.(1995-2000) Behandlungsmöglichkeiten bei HIV und AIDS. *Aids-Info Docu*, Schweiz 1995-2000.
2. Colombo C, Pei P, Jost J. Wassergeburten und HIV-Exposition *Pflege* 2000;13(3):152-9.
3. Desgandchamps D, Flepp M, Meister T. Sanford 2000/2001. Leitfaden der antimikrobiellen Behandlung. Übersetzung und Adaptation für die Schweiz von: Gilbert D.N., Moellering R.C. Jr., Sande M.A. *Guide to Antimicrobial Therapy* 2000, Hyde Park, USA, 2000.
4. Flepp M, Jost J, Hischel B, Weber R, Bernasconi E. für die Subkommission Klinik [SKK] der eidgenössischen Kommission für Aidsfragen [EKAF]: Empfehlungen zur antiretroviralen HIV –Therapie 2001. *Bulletin des Bundesamtes für Gesundheit* 2000;51:994-1000.
5. Grob P.J, Joller Jemelka H.I, Flepp M, Schanz U, Schüpbach J. Diagnostik der HIV-Infektion. *UZL-NEWS* 2000;1:1-5.
6. Pittet D, Ruef C. Erste nationale Studie zur Erfassung der Prävalenz nosokomialer Infektionen in Schweizer Universitätsspitalern. *Swiss-NOSO* 2000; 7: 1-3.
7. Ruef C. Bacterial meningitis – Problems on many fronts. *Infection* 2000;28:1-2.
8. Ruef C. Tick-Borne Viral Encephalitis – the Threat of Summer. *Infection* 2000;28:65-67.
9. Ruef C, Troillet N. Stellenwert der Filter bei mechanischer Beatmung. *Swiss-NOSO* 2000;7:4-5.
10. Ruef C. Unusual presentations of infectious diseases. *Infection* 2000;28:129-131.
11. Ruef C. Is antibiotic prophylaxis without risk? *Infection* 2000;28:259-260.
12. Ruef C. Nosocomial infections – multiple fields of activity. *Infection* 2000;28:339-340.
13. Schüpbach J, Tomasik Z, Nadal D, Ledergerber B, Flepp M, Opravil M, Böni J. Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. *Int J Antimicrob Agents* 2000;16:441-445.

Bücher und Buchbeiträge

1. Deplazes P, Mathis A, Weber R. Epidemiology and zoonotic aspects of Microsporidia of mammals and birds. *Contrib Microb Basel*, Karger, 2000;6:236-260.
2. Proudfoot AEI, Wells TN, Trkola A. Antagonism of chemokine receptors in preventing Infection by HIV. In: *Antivirals against AIDS*. Unger RE, Kreuter J, Rübsamen-Waigmann H (eds.) Marcel Dekker, Inc. 2000; 249-267.
3. Weber R, Schwartz DA, Bryan RT. Microsporidia, p. 2920-2933. In: Mandell GL, Bennett JE, Dolin R (eds.) *Principles and Practice of Infectious Diseases*. Churchill Livingstone, New York 2000.
4. Weber R, Lüthy R, Fontana A, Siegenthaler W. Status febrilis, p. 86-173. In: W. Siegenthaler (ed.) *Differentialdiagnose innerer Krankheiten*. Georg Thieme Verlag, Stuttgart 2000.
5. Weber R, Deplazes P, Schwartz D. Diagnosis and clinical aspects of human microsporidiosis. *Contrib. Microb. Basel*, Karger, 2000;6:166-192.